Linked Life Data

2236041

Source:http://linkedlifedata.com/resource/pubmed/id/2236041

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2236041rdf:typepubmed:Citationlld:pubmed
pubmed-article:2236041lifeskim:mentionsumls-concept:C0023493lld:lifeskim
pubmed-article:2236041lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2236041lifeskim:mentionsumls-concept:C0033808lld:lifeskim
pubmed-article:2236041lifeskim:mentionsumls-concept:C0229664lld:lifeskim
pubmed-article:2236041lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:2236041lifeskim:mentionsumls-concept:C0015309lld:lifeskim
pubmed-article:2236041lifeskim:mentionsumls-concept:C0021084lld:lifeskim
pubmed-article:2236041lifeskim:mentionsumls-concept:C0663182lld:lifeskim
pubmed-article:2236041lifeskim:mentionsumls-concept:C0314768lld:lifeskim
pubmed-article:2236041lifeskim:mentionsumls-concept:C1511636lld:lifeskim
pubmed-article:2236041pubmed:issue21lld:pubmed
pubmed-article:2236041pubmed:dateCreated1990-12-7lld:pubmed
pubmed-article:2236041pubmed:abstractTextAnti-Tac(Fv)-PE40 is a recombinant single-chain immunotoxin containing the heavy and light variable regions of the anti-Tac monoclonal antibody fused to a mutant form of Pseudomonas exotoxin (PE). Anti-Tac binds to the p55 subunit of the human interleukin 2 (IL-2) receptor, and anti-Tac(Fv)-PE40 kills human or monkey cell lines that contain either the intact IL-2 receptor or its p55 subunit alone. To assess the usefulness of anti-Tac(Fv)-PE40 in treatment of IL-2 receptor-positive leukemia, we tested peripheral blood mononuclear cells from six patients with adult T-cell leukemia. In each of the six patients, anti-Tac(Fv)-PE40 was extremely cytotoxic to the malignant cells. Metabolic activity and sensitivity of the fresh cells improved when a small amount of IL-2 (10 units per ml) was present during incubation. The toxin concentration necessary to inhibit protein synthesis by 50% after 16-hr incubation of cells with immunotoxin varied from 1.6 to 16 ng/ml (2.5-25 x 10(-11) M). In every case, binding was by means of the Tac antigen because anti-Tac(Fv)-PE40 cytotoxicity was prevented by adding excess anti-Tac antibody. Moreover, anti-Tac alone or an inactive mutant of anti-Tac(Fv)-PE40 without ADP-ribosylation activity had very little cytotoxic activity. Peripheral blood mononuclear cells from normal controls, from a patient with Tac-negative leukemia, and from adult T-cell leukemia patients without significant peripheral blood involvement were not sensitive to anti-Tac(Fv)-PE40. These results indicate that anti-Tac(Fv)-PE40 is a potent cytotoxin against adult T-cell leukemia cells in vitro and warrants clinical testing.lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:languageenglld:pubmed
pubmed-article:2236041pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:citationSubsetIMlld:pubmed
pubmed-article:2236041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2236041pubmed:statusMEDLINElld:pubmed
pubmed-article:2236041pubmed:monthNovlld:pubmed
pubmed-article:2236041pubmed:issn0027-8424lld:pubmed
pubmed-article:2236041pubmed:authorpubmed-author:PastanIIlld:pubmed
pubmed-article:2236041pubmed:authorpubmed-author:WillinghamM...lld:pubmed
pubmed-article:2236041pubmed:authorpubmed-author:WaldmannTTlld:pubmed
pubmed-article:2236041pubmed:authorpubmed-author:KreitmanR JRJlld:pubmed
pubmed-article:2236041pubmed:authorpubmed-author:FitzGeraldD...lld:pubmed
pubmed-article:2236041pubmed:authorpubmed-author:ChaudharyV...lld:pubmed
pubmed-article:2236041pubmed:issnTypePrintlld:pubmed
pubmed-article:2236041pubmed:volume87lld:pubmed
pubmed-article:2236041pubmed:ownerNLMlld:pubmed
pubmed-article:2236041pubmed:authorsCompleteYlld:pubmed
pubmed-article:2236041pubmed:pagination8291-5lld:pubmed
pubmed-article:2236041pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:meshHeadingpubmed-meshheading:2236041-...lld:pubmed
pubmed-article:2236041pubmed:year1990lld:pubmed
pubmed-article:2236041pubmed:articleTitleThe recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.lld:pubmed
pubmed-article:2236041pubmed:affiliationLaboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.lld:pubmed
pubmed-article:2236041pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2236041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2236041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2236041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2236041lld:pubmed